There is evidence that insulin resistance may develop after breast cancer adjuvant therapy [41], and a recent prospective study reported that increased resistin levels coincided with the concurrent increase in serum insulin and insulin resistance following treatment (surgery followed by chemotherapy and radiotherapy) among stage II–III breast cancer patients in an adiposity-independent way [35]. The gene discussed is RETN; the disease is breast carcinoma.